Search Results - "Lajoie, jason"

Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier by Lajoie, Jason M, Shusta, Eric V

“…Biologics are an emerging class of medicines with substantial promise to treat neurological disorders such as Alzheimer's disease, stroke, and multiple…”
Get full text

Identification of lamprey variable lymphocyte receptors that target the brain vasculature by Lajoie, Jason M., Katt, Moriah E., Waters, Elizabeth A., Herrin, Brantley R., Shusta, Eric V.

“…The blood–brain barrier (BBB) represents a significant bottleneck for the delivery of therapeutics to the central nervous system. In recent years, the promise…”
Get full text

A yeast display immunoprecipitation screen for targeted discovery of antibodies against membrane protein complexes by Lajoie, Jason M, Cho, Yong Ku, Frost, Dustin, Bremner, Samantha, Li, Lingjun, Shusta, Eric V

“…Yeast display immunoprecipitation is a combinatorial library screening platform for the discovery and engineering of antibodies against membrane proteins using…”
Get full text

Yeast Display-Based Antibody Affinity Maturation Using Detergent-Solubilized Cell Lysates by Tillotson, Benjamin J, Lajoie, Jason M, Shusta, Eric V

“…It is often desired to identify or engineer antibodies that target membrane proteins (MPs). However, due to their inherent insolubility in aqueous solutions,…”
Get more information

Introducing glycophage arrays: Facile production, purification and patterning of glycophages by Lajoie, Jason M., Shusta, Eric V.

“…Glycosylation is a widespread post-translational modification that plays important roles in health and disease. As glycan sequence and structure are not…”
Get full text

Identification of variable lymphocyte receptors that can target therapeutics to pathologically exposed brain extracellular matrix by Umlauf, Benjamin J, Clark, Paul A, Lajoie, Jason M, Georgieva, Julia V, Bremner, Samantha, Herrin, Brantley R, Kuo, John S, Shusta, Eric V

“…Diseases that lead to blood-brain barrier (BBB) disruption will pathologically expose normally inaccessible brain extracellular matrix (ECM) to circulating…”
Get full text

Queer(ing) medical spaces: queer theory as a framework for transformative social change in anesthesiology and critical care medicine by Hrynyk, Nicholas, Peel, John K., Grace, Daniel, Lajoie, Jason, Ng-Kamstra, Joshua, Kuper, Ayelet, Carter, Mic, Lorello, Gianni R.

“…Queer theory is a disruptive lens that can be adopted by researchers, educators, clinicians, and administrators to effect transformative social change. It…”
Get full text

Targeting Receptor-Mediated Transport for Delivery of Biologies Across the Blood-Brain Barrier by Lajoie, Jason M, Shusta, Eric V

“…Biologies are an emerging class of medicines with substantial promise to treat neurological disorders such as Alzheimer's disease, stroke, and multiple…”
Get full text

EXTH-67. IDENTIFICATION AND DEVELOPMENT OF NEURAL ECM-BINDING LAMPREY ANTIBODIES (VARIABLE LYMPHOCYTE RECEPTORS) THAT TARGET GLIOBLASTOMA by Umlauf, Benjamin, Clark, Paul, Lajoie, Jason, Georgieva, Julia, Bremner, Samantha, Herrin, Brantley, Shusta, Eric, Kuo, John

“…Abstract INTRODUCTION The median survival of glioblastoma (GBM) patients remains less than two years even with state-of-the-art treatment. Current targeted GBM…”
Get full text

Abstract 1528: Discovery and preclinical characterization of fratricide-resistant TRuC T-cells targeting CD70 by Ding, Jian, Watt, Amy, Liu, Erica, Adam, Zieba, McCarthy, Derrick, Gierut, Jessica, Schrand, Brett, Lofgren, Michael, Lajoie, Jason, Kenanova, Vania, Kiefer-Kwon, Philippe, Horton, Holly, Gutierrez, Dario A., Hofmeister, Robert, Tighe, Robert

“…Previously we have described the design and antitumor activity of T cell receptor fusion constructs (TRuC™) that tether an antibody-derived binder to one of…”
Get full text

SCIDOT-05. DEVELOPING VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET PATHOLOGICALLY EXPOSED NEURAL ECM TO TREAT GLIOBLASTOMA by J Umlauf, Benjamin, A Clark, Paul, M Lajoie, Jason, V Georgieva, Julia, Bremner, Samantha, R Herrin, Brantley, V Shusta, Eric, S Kuo, John

“…Abstract INTRODUCTION The median survival of gliobastoma (GBM) patients remains less than two years despite aggressive treatments. Current targeted GBM…”
Get full text

Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma by Draghi, Monia, Schafer, Jamie L., Nelson, Allison, Frye, Zach, Oliphant, Amanda, Haserlat, Sara, Lajoie, jason, rogers, Kenneth, Villinger, Francois, Schmidt, Michael, Tighe, Robert, Bobrowicz, Piotr, Watkins-Yoon, Jennifer, Schuetz, Thomas

“…Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells. Although several new drugs for the treatment of MM have greatly improved…”
Get full text

Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models by Eskiocak, Ugur, Guzman, Wilson, Daly, Thomas, Nelson, Allison, Bakhru, Pearl, Lajoie, Jason, Haserlat, Sara, Ottinger, Samantha, Liu, Lucy, Oliphant, Amanda, Leung, Alan, Hemashettar, Girish, Rennard, Rachel, Wolf, Benjamin, Draghi, Monia, Schmidt, Michael, Tighe, Robert

“…Blockade of inhibitory checkpoint pathways, such as PD-1/PD-L1 and CTLA-4, has provided significant benefit to subsets of patients and changed the cancer…”
Get full text

BTN3A1 governs anti-tumor responses by coordinating alpha-beta and gamma-delta T cells by Payne, Kyle K., Mine, Jessica A., Biswas, Subir, Chaurio, Ricardo A., Perales-Puchalt, Alfredo, Anadon, Carmen M., Costich, Tara Lee, Harro, Carly M., Walrath, Jennifer, Ming, Qianqian, Tcyganov, Evgenii, Buras, Andrea L., Rigolizzo, Kristen E., Mandal, Gunjan, Lajoie, Jason, Ophir, Michael, Tchou, Julia, Marchion, Douglas, Luca, Vincent C., Bobrowicz, Piotr, McLaughlin, Brooke, Eskiocak, Ugur, Schmidt, Michael, Cubillos-Ruiz, Juan R., Rodriguez, Paulo C., Gabrilovich, Dmitry I., Conejo-Garcia, Jose R.

“…Gamma delta (γδ) T-cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ MHC-independent tumoricidal potential…”
Get full text

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma by Watkins-Yoon, Jennifer, Guzman, Wilson, Oliphant, Amanda, Haserlat, Sara, Leung, Alan, Chottin, Claire, Ophir, Michael, Vekeria, Jai, Nelson, Allison P, Frye, Zach, Lajoie, Jason, Nanjappa, Puru, Lama, Sujan, Markrush, Dalton, McConaughy, William, Wang, Xianzhe, Schilling, Neal, Kim, Doyeob, Wu, Paul, Liu, Lucy, Rogers, Kenneth, Villinger, Francois, Gong, Bing, Hamilton, Stephen, Bobrowicz, Piotr, Schuetz, Thomas, Schmidt, Michael, Draghi, Monia

“…Introduction: Current therapies for multiple myeloma (MM), such as immunomodulatory agents, proteasome inhibitors, stem-cell transplantation, and monoclonal…”
Get full text

Butyrophilin 3A1 is a Dynamic T Cell Regulator in Ovarian Cancer by Payne, Kyle K, Gonzalez, Ricardo Chaurio, Sanz, Jairo Perez, Galindo, Carmen Maria Anadon, Biswas, Subir, Mine, Jessica A, Perales-Puchalt, Alfredo, Tsiganov, Evgenii, Costich, Tara Lee, Harro, Carly M, Marrs, Aubrey K, Lajoie, Jason, Li, Kun-Po, Ophir, Michael, Eskiocak, Ugur, Schmidt, Michael, Gabrilovich, Dmitry I, Conejo-Garcia, Jose R

“…Ovarian carcinoma microenvironmental T cells exert clinically relevant pressure against malignant progression; however current immunotherapies rarely induce…”
Get full text

BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells by Payne, Kyle K, Mine, Jessica A, Biswas, Subir, Chaurio, Ricardo A, Perales-Puchalt, Alfredo, Anadon, Carmen M, Costich, Tara Lee, Harro, Carly M, Walrath, Jennifer, Ming, Qianqian, Tcyganov, Evgenii, Buras, Andrea L, Rigolizzo, Kristen E, Mandal, Gunjan, Lajoie, Jason, Ophir, Michael, Tchou, Julia, Marchion, Douglas, Luca, Vincent C, Bobrowicz, Piotr, McLaughlin, Brooke, Eskiocak, Ugur, Schmidt, Michael, Cubillos-Ruiz, Juan R, Rodriguez, Paulo C, Gabrilovich, Dmitry I, Conejo-Garcia, Jose R

“…Gamma delta (γδ) T cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ major histocompatibility complex-independent…”
Get full text

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity by Eskiocak, Ugur, Guzman, Wilson, Wolf, Benjamin, Cummings, Christine, Milling, Lauren, Wu, Hsin-Jung, Ophir, Michael, Lambden, Conner, Bakhru, Pearl, Gilmore, Dana C, Ottinger, Samantha, Liu, Lucy, McConaughy, William K, He, Sunny Q, Wang, Chao, Leung, Cheuk Lun, Lajoie, Jason, Carson, 4th, William F, Zizlsperger, Nora, Schmidt, Michael M, Anderson, Ana C, Bobrowicz, Piotr, Schuetz, Thomas J, Tighe, Robert

“…CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Recent insights into the function of TNFR…”
Get full text

Application of Yeast Surface Display Screening Methods to Antibody Discovery and Proteomics of the Blood-Brain Barrier by Lajoie, Jason M

“…The blood-brain barrier (BBB), comprised of tightly joined endothelial cells lining the brain vasculature, represents a significant bottleneck in the…”
Get full text

Critical by design: Fostering responsible innovation with critical design methods by O'Gorman, Marcel, Lajoie, Jason, Pearl, Zach

“…Summary form only given, as follows. A complete record of the panel discussion was not made available for publication as part of the conference proceedings…”
Get full text